These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 17098845)
21. Use of electroconvulsive therapy in Parkinson disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study. Pintor LP; Valldeoriola F; Fernández-Egea E; Sánchez R; Rami L; Tolosa E; Muñiz A; Martí MJ; Bernardo M J ECT; 2012 Jun; 28(2):87-91. PubMed ID: 22531200 [TBL] [Abstract][Full Text] [Related]
22. Dopaminergic and non-dopaminergic gait components assessed by instrumented timed up and go test in Parkinson's disease. Dibilio V; Nicoletti A; Mostile G; Toscano S; Luca A; Raciti L; Sciacca G; Vasta R; Cicero CE; Contrafatto D; Zappia M J Neural Transm (Vienna); 2017 Dec; 124(12):1539-1546. PubMed ID: 29018993 [TBL] [Abstract][Full Text] [Related]
23. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: three years follow-up. Gan J; Xie-Brustolin J; Mertens P; Polo G; Klinger H; Mollion H; Benatru I; Henry E; Broussolle E; Thobois S J Neurol; 2007 Jan; 254(1):99-106. PubMed ID: 17508144 [TBL] [Abstract][Full Text] [Related]
24. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. Evans AH; Lawrence AD; Lees AJ J Neurol Neurosurg Psychiatry; 2009 Mar; 80(3):267-72. PubMed ID: 18977820 [TBL] [Abstract][Full Text] [Related]
25. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Stefani A; Lozano AM; Peppe A; Stanzione P; Galati S; Tropepi D; Pierantozzi M; Brusa L; Scarnati E; Mazzone P Brain; 2007 Jun; 130(Pt 6):1596-607. PubMed ID: 17251240 [TBL] [Abstract][Full Text] [Related]
26. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease. Yamada K; Goto S; Hamasaki T; Kuratsu JI Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867 [TBL] [Abstract][Full Text] [Related]
27. Improvement in Language Function Correlates with Gait Improvement in Drug-naïve Parkinson's Disease Patients Taking Dopaminergic Medication. Murakami H; Momma Y; Nohara T; Mori Y; Futamura A; Sugita T; Ishigaki S; Katoh H; Kezuka M; Ono K; Miller MW; Kawamura M J Parkinsons Dis; 2016; 6(1):209-17. PubMed ID: 26889633 [TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin type B for gait freezing in Parkinson's disease. Fernandez HH; Lannon MC; Trieschmann ME; Friedman JH Med Sci Monit; 2004 Jul; 10(7):CR282-4. PubMed ID: 15232500 [TBL] [Abstract][Full Text] [Related]
29. Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Plaha P; Ben-Shlomo Y; Patel NK; Gill SS Brain; 2006 Jul; 129(Pt 7):1732-47. PubMed ID: 16720681 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: A single-arm, open-label, prospective, multicenter study. Iijima M; Orimo S; Terashi H; Suzuki M; Hayashi A; Shimura H; Mitoma H; Kitagawa K; Okuma Y Expert Opin Pharmacother; 2019 Aug; 20(11):1405-1411. PubMed ID: 31039621 [No Abstract] [Full Text] [Related]
32. STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Moreau C; Defebvre L; Destée A; Bleuse S; Clement F; Blatt JL; Krystkowiak P; Devos D Neurology; 2008 Jul; 71(2):80-4. PubMed ID: 18420482 [TBL] [Abstract][Full Text] [Related]
33. The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson's disease. Matsuura K; Kajikawa H; Tabei KI; Satoh M; Kida H; Nakamura N; Tomimoto H Neurosci Lett; 2018 Jan; 662():158-161. PubMed ID: 29031781 [TBL] [Abstract][Full Text] [Related]